Derek Nexus and Sarah Nexus: working together for ICH M7

Similar documents
is a knowledge based expert decision support tool for predicting the metabolic fate of chemicals in mammals.

ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK

Chemical Risk Assessment in Absence of Adequate Toxicological Data

EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE

Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy

IMPURITIES IN NEW DRUG PRODUCTS

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations

What s New with Impurities in Pharmaceuticals?

QSAR Application Toolbox Workflow. Laboratory of Mathematical Chemistry, Bourgas University Prof. Assen Zlatarov Bulgaria

Importing pharmaceutical products to China

Rapid Pharma Development GmbH. Impurities in the contexts of CMC Development

Guidance for Industry

Regulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc.

Read-across and alternative testing strategies for REACH 2018

How to create and interpret the predictive analysis of a compound

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency

Practical Guide 6. How to report read-across and categories

General Principles for the Safety Assessment of Excipients

Guidance for Industry Safety Testing of Drug Metabolites

Risk assessment and regulation of tattoo inks in the EU

A FDA Perspective on Nanomedicine Current Initiatives in the US

Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity

Working with ICH Quality Guidelines - the Canadian Perspective

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

Overview of Drug Development: the Regulatory Process

TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS

Guidance for Industry

Division of Bioinformatics and Biostatistics

REACH. Scope REGISTRATION. The Current EU Chemicals Policy REACH

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

CTD Dossier Preparation. Sr.Manager-Regulatory Affairs

Examples from Industrial Practice in Lead Development. Wolfgang Muster F. Hoffmann-La Roche Ltd.

MedDRA in pharmacovigilance industry perspective

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

Submission of scientific peer-reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 1, 2

Biological importance of metabolites. Safety and efficacy aspects

Medicine Safety Glossary

Guidance for Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Impurity Profiles in Active Pharmaceutical Ingredients

Validating Methods using Waters Empower TM 2 Method. Validation. Manager

Drug Information Journal, Vol. 33, pp , /99

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS

Implementation strategy for ISO IDMP in EU

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

ICH Public Meeting. Joseph C. Famulare. October 2, Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance

Strategic Benefits of an Online Clinical Data Repository

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

Getting Ready for REACH Advanced Solutions for Compliance. John Phyper, CSO & EVP Atrion International Inc.

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

Guidance for Industry

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES Division of Extramural Research and Training

Q8(R2): Pharmaceutical Development

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD

Chapter 12: SPECIFIC TARGET ORGAN SYSTEMIC TOXICITY (TOST) FOLLOWING A SINGLE EXPOSURE

Risk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS)

Lead optimization services

ANTARES A new project for Alternative Methods and REACH

Use of Predictive ADME in Library Profiling and Lead Optimization

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences

Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.

Ah-Reum Seo of Chemservice Asia introduces the forthcoming chemicals regulation for South Korea

Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP)

ROADMAP. A. Context and problem definition

Current version dated 5 March 2012

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15

ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

Chemical Screening Visualization Tool: Resource for Rapid Chemical Assessment

Non-clinical development of biologics

Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS

Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe

Workshop B Control Strategy

Collaborations between Official Statistics and Academia in the Era of Big Data

Roles & Responsibilities of the Sponsor

Cheminformatics and its Role in the Modern Drug Discovery Process

Dr Alexander Henzing

Auditing as a Component of a Pharmaceutical Quality System

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

Transcription:

Derek Nexus and Sarah Nexus: working together for ICH M7 European ICGM, September 2014 Dr Nicholas Marchetti Product Manager nik.marchetti@lhasalimited.org

Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

What does M7 cover? identification categorisation qualification Control of mutagenic impurities to limit potential carcinogenic risk Harmonises guidelines FDA, EMA, Japan Recognises the primacy of the Ames assay

Focussing on the identification step Evaluate drug substance, impurities, degradants, (metabolites), intermediates Databases, in-house, literature.. 2 x in silico QSAR Leadscope Multicase Known mutagen Predicted positive Predicted negative Known non-mutagen Expert Review Ames test Expert Review Limit according to TTC or present purge argument for absence Treat as nonmutagenic

Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

Vitic Nexus an authoritative toxicity database Vitic Nexus is a repository of toxicological data Data donated by members Curated and augmented by expert scientists Genotoxicity records In vitro data In vivo data Overall call 146,444 records, 9,014 compounds 10,157 records, 2,658 compounds 15,289 records, 8,510 compounds Contains public datasets and literature including Benchmark, CGX, ISSSTY, IUCLID FDA CDER & CFSAN, JETOC (Japanese Chemical Industry Ecology-Toxicology..) IARC, JETOC, NIHS, NTP, SCCP, SIDS Members also store their own data in Vitic Nexus

Data sharing consortia Lhasa facilitate pre-competitive data sharing Members of these consortia also see Aromatic amines 1,664 records 145 compounds Intermediates (includes boronic acid sub-group) 13,834 records 910 compounds Excipients 2,286 records 764 compounds

in silico predictions for M7 Use models that predict Ames outcomes 2 complementary methods should be applied One expert rule-based One statistical-based Models should follow OECD Principles for QSAR The absence of alerts from both is sufficient to conclude that the impurity is of no concern Expert review is needed to provide additional evidence for any prediction and to explain conflicting results

Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

Enhancing Derek Nexus for mutagenicity Designed to support expert analysis for M7 Provide additional supporting information Recommend where expert should focus analysis

Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

Sarah Nexus an advanced statistical system Designed to address the ICH M7 guidelines Created with input from the FDA under a Research Collaboration Agreement

Making a prediction Query compounds are fragmented Each fragment is assessed Fragments not covered by the training set result in no prediction Relevant hypotheses for each fragment are retrieved Hypothesis, signal, confidence, supporting examples Typically several hypotheses are returned out of domain Overall Prediction = f (prediction, confidence) hypotheses Absence of a strong overall signal equivocal

Confidence correlates with accuracy TN 29% TP 31% FP 22% FN 18% TN 40% FP 13% TP 37% FN 10% TN 39% FP 9% TP 50% FN 2% TN 34% FP 4% TP 60% FN 2% FP 6% TN 23% TP 70% FN 1% 1 b. aaa = ssss + ssss 2 0.8 PPP = TT TT + FF 0.6 NNN = TT TT + FF 0.4 0.2 0 0-20% 20-40% 40-60% 60-80% 80-100% Sarah confidence score

Confidence vs PPV 100% 90% 80% 70% PPV 60% 50% 40% 30% 20% 10% 0% 0% 20% 40% 60% 80% 100% Confidence

Sarah Nexus Performance Sarah Nexus has been extensively evaluated by members 100% 80% 83-96% 60-85% 60-89% 38-84% 60% Private 1, n= 744, 28% +ive Private 2, n = 847, 12% +ive Private 3, n= 437, 16% +ive 40% 20% 0% sens + spec 2 TN TN + FP TP TP + FN Coverage Balanced accuracy Specificity Sensitivity Private 4, n = 986, 4% +ive Private 5, n = 1718, 14% +ive Private 6, n = 320, 23% +ive FDA, n=809, 36% +ive Public, n = 11209,49% +ive Sarah Nexus v1 under recommended settings Presented @ SoT, March 2014

Sarah Nexus - Summary Sarah is a statistical approach to mutagenicity Maintains high coverage even with challenging datasets Provides information needed for expert analysis

The use of integrated in silico solutions under the proposed ICH M7 guidelines OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

Using in silico predictions M7 explicitly states that in silico predictions should be reviewed with expert knowledge Provide supportive evidence for any prediction Elucidate underlying reasons in case of conflicting results But how will this work in real life? In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey Regulatory Toxicology and Pharmacology, 2012, 62, 449 455 Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities Regulatory Toxicology and Pharmacology, 2013, 67, 39

2 complementary methodologies should be applied Data methodology Expert system uses all Lhasa data including consortia & donated confidential data + data mined on-site expert system human-written rules based upon data & knowledge Statistical system only uses non-confidential data statistical model machine-learning model using a hierarchical network scope of alert hand-written Markush fragments learnt by model interpretability references expert commentary mechanistic explanation scope of alert some supporting examples transparent methodology learning summarised by hypothesis direct link to training set confidence in prediction

Using Sarah and Derek together How often do they disagree? When they agree, how accurate are they? 100% 69-85% 62-90% 80% 60% 40% 20% Private Dataset 1 Private Dataset 2 Private Dataset 3 Public Dataset 0% Agreement between Derek Nexus and Sarah Nexus Balanced accuracy for concurring predictions Acknowledgements : All the Lhasa members who worked closely with us during the evaluation and development of Sarah

Using Sarah and Derek together A simple conservative approach will increase sensitivity sensitivity 1..but at the cost of accuracy and specificity 0.9 0.68, 0.8 0.7 0.72 = 0.83 0.6 0.74 0.5 0.4 0.3 0.2 0.1 0 Private dataset 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 accuracy specificity

Using Sarah and Derek together When they disagree, which is right? Public Dataset Private Dataset 3 7% 14% 7% 7% 11% 9% 5% 7% 9% 72% 73% 80% 31% 25% 17% 27%

Handling conflicting predictions Confidence scores can give an indication Machine-learnt & expert driven rules have been assessed If both models agree Take that consensus prediction If one model has a high confidence prediction Take the most confident prediction If Derek says positive and Sarah has a positive hypothesis (despite being negative overall) Activity is most likely If the positive prediction is of low confidence Activity is unlikely.

Handling conflicting predictions Private Dataset 1 Step 1 0.85 0.8 Step 2 Step 3 Step 4 D and S agree Most confident prediction D says positive, S has positive hypothesis Low confidence positive 0.75 0.7 0.65 0.6 0.55 0.5 Accuracy Sensitivity True accuracy Coverage Simple rules give increased coverage without loss of accuracy

Ultimately, expert review is needed Decision trees may help guide an expert, but expert review is still essential We have worked with our members to deliver the information needed for expert review

Supporting the expert workflow Step 1 Specific Prediction for ICH M7

Supporting the expert workflow Derek prediction Predicted negative but there is a ring system to assess

Supporting the expert workflow Derek Nexus now shows those compounds from the Lhasa Ames test reference set most closely related to the query

Supporting the expert workflow Step 2 Sarah prediction Sarah predicts negative; no positive hypotheses seen Derek and Sarah analysis agree Supporting data from Vitic augments this prediction

Supporting the expert workflow Step 3 Vitic search similarity chosen Vitic shows a related active for which there is no obvious cause (no Derek alert fires) and also a related inactive Expert assessment ring system not of concern

Possible reasons to over-rule a positive in silico call The presence of a second confounding alert that could have caused the activity a risk with statistical models Minimised with Sarah s recursive learning approach Mechanistic interpretation stereo-electronics preclude reaction through the accepted mechanism such as that described within Derek Similar analogues trigger the same alert and have been tested as inactive were not known to the model

What our members say Combined use of two complementary in silico systems such as Derek Nexus and SEP leads to an increase in negative predictivity and sensitivity, up to 99.1% and 94.7% respectively Poster Comparative Evaluation of in Silico Systems for Ames Test Mutagenicity Prediction Ilse Koijen Janssen, GTA Newark Oct 2013, www.gta-us.org/scimtgs/2013meeting/posters2013.html SEP = the pre-release version of Sarah

Combined report view

Derek Prediction

Sarah Prediction

Batch View

Paper reports

Summary M7 will allow predictions of mutagenicity to be submitted Derek has been extended to increase support for expert review Making confident predictions of inactivity Highlighting features worthy of attention Sarah has been designed to provide the statistical 2 nd system Recursive learning and a hierarchical network provide transparency and accuracy The performance of combined predictions has been described Using a number of relevant confidential datasets Examples of expert decision-making illustrate their application Use of Vitic, an authoritative database supports this workflow

Questions?